D

Dicerna Pharmaceuticals Inc
F:DPL

Watchlist Manager
Dicerna Pharmaceuticals Inc
F:DPL
Watchlist
Price: 33.51 EUR Market Closed
Market Cap: 2.6B EUR

Net Margin
Dicerna Pharmaceuticals Inc

-64.5%
Current
-517.6%
Average
-6.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-64.5%
=
Net Income
-124.4m
/
Revenue
192.9m

Net Margin Across Competitors

No Stocks Found

Dicerna Pharmaceuticals Inc
Glance View

Market Cap
2.6B EUR
Industry
Biotechnology

In the unassuming landscape of biotechnology, Dicerna Pharmaceuticals Inc. carved its niche with the finesse of a sculptor hewing masterpieces from marble. Founded in 2007, this Lexington-based company embarked on its journey into the realm of RNA interference (RNAi) therapies, a revolutionary approach that tackles diseases by silencing specific genes. RNAi is akin to flipping a switch within our genetic blueprint, modulating the expression of proteins that could potentially cause disorders. Dicerna's proprietary GalXC™ technology emerged as the linchpin of its innovation, allowing the company to create targeted therapies that had the potential to address a diverse array of rare and chronic diseases such as primary hyperoxaluria, chronic liver diseases, and viral infections. Dicerna's business model weaved together research prowess and strategic alliances, capitalizing on partnerships with big pharmaceutical titans like Novo Nordisk, Roche, Boehringer Ingelheim, and Eli Lilly to propel its research pipeline. These collaborations not only provided the necessary capital but also amplified its scientific discoveries to reach broader horizons. Licensing agreements allowed Dicerna to earn milestone payments along with royalties on eventual sales, enabling it to reinvest in groundbreaking research and development. While playing the long game in the volatile waters of biotechnology, Dicerna's revenue strategy relied heavily on these partnerships, as well as on advancing its in-house programs to bring its therapies closer to market, painting a picture of a company poised at the confluence of scientific promise and commercial potential.

DPL Intrinsic Value
Not Available
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-64.5%
=
Net Income
-124.4m
/
Revenue
192.9m
What is the Net Margin of Dicerna Pharmaceuticals Inc?

Based on Dicerna Pharmaceuticals Inc's most recent financial statements, the company has Net Margin of -64.5%.

Back to Top